News & Innovations

News and innovations published by German exhibitors

  back to overview

New HTS Platform for Personalized Tumor Therapy

The Division of Personalized Tumor Therapy of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, based at the BioPark Regensburg, has founded a new working group “High-Throughput Drug and Target Discovery”. Its goal is to generate patient-derived preclinical in-vitro models for a multitude of cancer types and to subsequently use these in high-throughput drug and target screening campaigns for personalized tumor therapy.

The Division of Personalized Tumor Therapy was founded in 2010 as a research partnership between the Fraunhofer-Gesellschaft, the State Government of Bavaria, and the University of Regensburg with the support of the City of Regensburg. The group of researchers took their first premises at the BioPark, an enterprise of the City of Regensburg. From its beginning, the group has been organizationally affiliated with Fraunhofer ITEM in Hannover as a project group, funded by the State of Bavaria. After successful evaluation of the project group, it became a division of Fraunhofer ITEM in 2017, dedicated to its own research topic and headed by Prof. Dr. Christoph Klein, who also holds the Chair of Experimental Medicine and Therapy Research at the University of Regensburg.

Further reading

Exhibitor: BioPark Regensburg

OK

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection